Matthew R. Henn, See Remarks at Seres Therapeutics, Inc. (MCRB), sold 927 shares at $0.54 ($501) on 2024-11-18, disclosed to the SEC on 2024-11-19.
Scheduled sale ($501) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MCRB | SELL | 2024-08-19 | $775 | — | Filing → |
| MCRB | SELL | 2024-05-17 | $838 | — | Filing → |
| MCRB | SELL | 2024-02-16 | $5K | — | Filing → |